Aktis Oncology, Inc. AKTS
17.04 USD -0.41 (-2.35%)
At closeNov 11, 2026, 4:01 PM EST
17.04 0.00 0.00%
After hours · Nov 11, 4:01 PM ET
17.03 Day range 17.87
14.59 52-week range 32.23
- YTD
- -23.93%
- 1 year
- -23.93%
News
zacks.com Does Aktis (AKTS) Have the Potential to Rally 105.62% as Wall Street Analysts Expect? The mean of analysts' price targets for Aktis (AKTS) points to a 105.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts…
seekingalpha.com Aktis Oncology: Padcev Is Building The Market It Wants Aktis Oncology is undervalued, trading below IPO price despite robust cash reserves and two independent clinical programs. AKTS has a cash runway into 2029, supported by $517.3M in cash and a $1.2B+…
benzinga.com Wedbush Reiterates Outperform on Aktis Oncology, Maintains $35 Price Target Wedbush analyst David Nierengarten reiterates Aktis Oncology (NASDAQ:AKTS) with a Outperform and maintains $35 price target.
benzinga.com Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519 Phase 1b BActinium-2 clinical trial is evaluating AKY-2519 in patients with non-small cell lung cancer (NSCLC) and other B7-H3 expressing tumorsEnrollment is ongoing in the Phase 1b BActinium-1…
globenewswire.com Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3 Phase 1b BActinium-2 clinical trial is evaluating AKY-2519 in patients with non-small cell lung cancer (NSCLC) and other B7-H3 expressing tumors Enrollment is ongoing in the Phase 1b BActinium-1…
seekingalpha.com Aktis Oncology, Inc. (AKTS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Aktis Oncology, Inc. (AKTS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript- benzinga.com Oppenheimer Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $40 Oppenheimer analyst Jeff Jones initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outperform rating and announces Price Target of $40.
benzinga.com Wedbush Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $35 Wedbush analyst David Nierengarten initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outperform rating and announces Price Target of $35.
benzinga.com BMO Capital Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $37 BMO Capital analyst David Lebowitz initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outperform rating and announces Price Target of $37.
investopedia.com Bank of America Sees Bargains in These 16 Knocked-Down AI Stocks A pullback in the AI trade has created opportunities for bargain-hunting investors, according to analysts at Bank of America.
benzinga.com Micron and 15 Other Stocks To Play The AI Buildout Race: They Are Still 20% Below Highs Bank of America screened its AI baskets for Buy-rated stocks down over 20% from highs. Micron carries the widest gap to target.
benzinga.com Aktis Oncology Q2 EPS $(0.44) Misses $(0.43) Estimate, Sales $3.384M Beat $2.000M Estimate Aktis Oncology (NASDAQ:AKTS) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.43) by 2.33 percent. This is a 98.03 percent increase over losses of…
globenewswire.com Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026 BOSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (“Aktis” or the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted…
benzinga.com DigitalOcean, Agios Pharmaceuticals, Kingsoft Cloud And Other Big Stocks Moving Higher On Tuesday US stocks were mixed, Nasdaq fell 1%. DigitalOcean shares rose after strong revenue growth and earnings guidance. Other big gainers include CRNX, MAAS, and AGIO.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Vicore Pharma Holding (NASDAQ:VCRE) stock rose 149.8% to $42.47 during Monday's after-market session. Crinetics Pharmaceuticals (NASDAQ:CRNX) stock moved upwards by 99.85% to $84.0. The…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Innovative Eyewear (NASDAQ:LUCY) stock moved upwards by 95.4% to $1.49 during Monday's regular session. The market value of their outstanding shares is at $4.8 million. Seer (NASDAQ:SEER)…
benzinga.com This Aktis Oncology Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday Top Wall Street analysts changed outlook on top names. For all changes, including upgrades/downgrades, visit analyst ratings page. Consider buying AKTS stock? Analysts weigh in.
benzinga.com Rezolve AI, Bakkt, Seagate And Other Big Stocks Moving Higher On Friday U.S. stocks were mixed, with the Dow Jones gaining 100 points. Rezolve AI (RZLV) jumped 11.9%, and other stocks such as ALOY and FWRD also rose.
seekingalpha.com Aktis Oncology: Mini-Proteins With A Targeted Punch Aktis Oncology trades at a $1.1B market cap with $540M cash, pricing its pipeline and Eli Lilly collaboration at $560M. The investment thesis hinges on the mini-protein platform targeting Nectin-4,…- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
globenewswire.com Aktis Oncology to Present at the Jefferies Global Healthcare Conference BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted…
globenewswire.com Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted…
fool.com Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company This clinical-stage biotech develops targeted radiopharmaceutical therapies for cancer using a proprietary miniprotein platform.
globenewswire.com Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026 BOSTON, May 11, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted…
globenewswire.com Aktis Oncology to Present at the BofA Securities Health Care Conference BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted…
globenewswire.com Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC) BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted…
benzinga.com This Hyperfine Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Wednesday Top analysts change outlook on Hyperfine Inc, Legence, and Aktis Oncology with Buy/Outperform ratings and price targets. See other analysts' views.
seekingalpha.com Aktis Oncology: 'Buy' Based On Radiotherapeutic Isotope Design For Broad Targeting Aktis Oncology is initiated with a "Buy" rating, driven by its innovative miniprotein radioconjugates targeting Nectin-4 and B7-H3 solid tumors. The company expects key catalysts: AKY-1189 phase 1b…
zacks.com Wall Street Analysts Predict a 74.73% Upside in Aktis (AKTS): Here's What You Should Know The mean of analysts' price targets for Aktis (AKTS) points to a 74.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts…
globenewswire.com Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors BOSTON, April 16, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted…
globenewswire.com Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted…
benzinga.com This Aktis Oncology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Top analysts change outlook on top names. See all analyst rating changes on Benzinga's analyst ratings page. Consider AKTS stock based on analyst views.
globenewswire.com Aktis Oncology to Present at Upcoming March Investor Conferences BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to…
globenewswire.com Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to…
benzinga.com This GCI Liberty Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday - benzinga.com Crude Oil Down 1%; Webuy Global Shares Spike Higher
- benzinga.com Why Uxin Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
benzinga.com 12 Information Technology Stocks Moving In Thursday's Pre-Market Session 
benzinga.com 12 Information Technology Stocks Moving In Tuesday's Intraday Session - benzinga.com 12 Information Technology Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Information Technology Stocks Moving In Thursday's Intraday Session
benzinga.com 12 Information Technology Stocks Moving In Wednesday's Pre-Market Session - benzinga.com Why JD.com Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
benzinga.com 12 Information Technology Stocks Moving In Tuesday's Intraday Session - benzinga.com Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
- benzinga.com Nasdaq Surges Over 100 Points; Nvidia Posts Upbeat Q1 Results
- benzinga.com Why NVIDIA Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket
- benzinga.com Why XP Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
- benzinga.com Why Urban Outfitters Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
- benzinga.com 12 Information Technology Stocks Moving In Monday's After-Market Session